JP2009542613A - 新規化合物 - Google Patents

新規化合物 Download PDF

Info

Publication number
JP2009542613A
JP2009542613A JP2009517423A JP2009517423A JP2009542613A JP 2009542613 A JP2009542613 A JP 2009542613A JP 2009517423 A JP2009517423 A JP 2009517423A JP 2009517423 A JP2009517423 A JP 2009517423A JP 2009542613 A JP2009542613 A JP 2009542613A
Authority
JP
Japan
Prior art keywords
optionally substituted
group
alkyl
optionally
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542613A5 (enExample
Inventor
ハルソール,クリストファー・トーマス
ラッジ,デイヴィッド・アラン
シンプソン,イアイン
ウォード,リチャード・アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2009542613A publication Critical patent/JP2009542613A/ja
Publication of JP2009542613A5 publication Critical patent/JP2009542613A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
JP2009517423A 2006-07-06 2007-07-05 新規化合物 Pending JP2009542613A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81887806P 2006-07-06 2006-07-06
PCT/GB2007/002490 WO2008003958A2 (en) 2006-07-06 2007-07-05 Fused pyrimido compounds

Publications (2)

Publication Number Publication Date
JP2009542613A true JP2009542613A (ja) 2009-12-03
JP2009542613A5 JP2009542613A5 (enExample) 2010-08-05

Family

ID=38857945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517423A Pending JP2009542613A (ja) 2006-07-06 2007-07-05 新規化合物

Country Status (19)

Country Link
US (1) US7709471B2 (enExample)
EP (1) EP2046793A2 (enExample)
JP (1) JP2009542613A (enExample)
KR (1) KR20090038895A (enExample)
CN (1) CN101511836A (enExample)
AR (1) AR061850A1 (enExample)
AU (1) AU2007270931A1 (enExample)
BR (1) BRPI0714045A2 (enExample)
CA (1) CA2656936A1 (enExample)
CL (1) CL2007001973A1 (enExample)
EC (1) ECSP099044A (enExample)
IL (1) IL196207A0 (enExample)
MX (1) MX2009000220A (enExample)
NO (1) NO20090052L (enExample)
RU (1) RU2009103810A (enExample)
TW (1) TW200808325A (enExample)
UY (1) UY30472A1 (enExample)
WO (1) WO2008003958A2 (enExample)
ZA (1) ZA200900073B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536760A (ja) * 2007-08-15 2010-12-02 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患の処置のための、ヒトタンパク質キナーゼplk1ないしplk4の阻害剤としての4−(9−(3,3−ジフルオロシクロペンチル)−5,7,7−トリメチル−6−オキソ−6,7,8,9−テトラヒドロ−5h−ピリミド[4,5−b[1,4]ジアゼパン−2−イルアミノ]−3−メトキシベンザミド誘導体
JP2010540509A (ja) * 2007-09-28 2010-12-24 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
JP2023515621A (ja) * 2020-02-28 2023-04-13 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
JP2023540728A (ja) * 2021-08-10 2023-09-26 オップテラ インコーポレイテッド 新規plk1分解誘導化合物

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
DK2049500T3 (da) 2006-07-06 2011-12-12 Array Biopharma Inc Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
SI2054418T1 (sl) 2006-07-06 2012-02-29 Array Biopharma Inc Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
PT2139892E (pt) * 2007-03-22 2011-11-21 Takeda Pharmaceutical Pirimidodiazepinas substituídas úteis como inibidores da plk1
KR20150091196A (ko) 2007-07-05 2015-08-07 어레이 바이오파마 인크. Akt 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ584760A (en) * 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
KR101624752B1 (ko) 2008-01-09 2016-05-26 어레이 바이오파마 인크. Akt 단백질 키나제 저해물질로써의 수산화된 피리미딜 시클로펜탄
CA2711699A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
AU2009322346B2 (en) * 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
TWI399551B (zh) * 2009-06-26 2013-06-21 Senao Networks Inc Burner device and burner method
AU2010299579A1 (en) * 2009-09-25 2012-05-03 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
NZ599342A (en) * 2009-09-25 2014-04-30 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
US20110218295A1 (en) * 2010-03-02 2011-09-08 Basf Se Anionic associative rheology modifiers
US8673275B2 (en) 2010-03-02 2014-03-18 Basf Se Block copolymers and their use
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2012135759A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
GB201205752D0 (en) * 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10112948B2 (en) 2015-07-06 2018-10-30 The Board Of Regents Of The University Of Texas System Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
KR20240096913A (ko) * 2021-08-30 2024-06-26 레믹스 테라퓨틱스 인크. 스플라이싱 조절을 위한 화합물 및 방법
CN113999244B (zh) * 2021-12-30 2022-05-20 北京鑫开元医药科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物及其制备方法
CN114392258B (zh) * 2021-12-30 2024-04-16 北京朗瑞邦科技有限公司 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物药物制剂及其制备方法
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔5,4-b〕吡啶malt-1抑制劑

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531928A (en) 2001-09-04 2005-10-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA05009068A (es) 2003-02-26 2005-10-19 Boehringer Ingelheim Pharma Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021547A1 (de) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
KR20080095902A (ko) * 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536760A (ja) * 2007-08-15 2010-12-02 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患の処置のための、ヒトタンパク質キナーゼplk1ないしplk4の阻害剤としての4−(9−(3,3−ジフルオロシクロペンチル)−5,7,7−トリメチル−6−オキソ−6,7,8,9−テトラヒドロ−5h−ピリミド[4,5−b[1,4]ジアゼパン−2−イルアミノ]−3−メトキシベンザミド誘導体
JP2010540509A (ja) * 2007-09-28 2010-12-24 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
JP2014076994A (ja) * 2007-09-28 2014-05-01 Cyclacel Ltd プロテインキナーゼ阻害剤としてのピリミジン誘導体
JP2023515621A (ja) * 2020-02-28 2023-04-13 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
JP7736700B2 (ja) 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
JP2023540728A (ja) * 2021-08-10 2023-09-26 オップテラ インコーポレイテッド 新規plk1分解誘導化合物
JP2023540729A (ja) * 2021-08-10 2023-09-26 オップテラ インコーポレイテッド 新規plk1分解誘導化合物
JP7555156B2 (ja) 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規plk1分解誘導化合物
JP7555155B2 (ja) 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規plk1分解誘導化合物

Also Published As

Publication number Publication date
AR061850A1 (es) 2008-09-24
CN101511836A (zh) 2009-08-19
WO2008003958A2 (en) 2008-01-10
TW200808325A (en) 2008-02-16
AU2007270931A1 (en) 2008-01-10
US7709471B2 (en) 2010-05-04
BRPI0714045A2 (pt) 2012-12-11
WO2008003958A3 (en) 2008-03-06
ZA200900073B (en) 2010-06-30
RU2009103810A (ru) 2010-08-20
MX2009000220A (es) 2009-01-22
NO20090052L (no) 2009-01-28
KR20090038895A (ko) 2009-04-21
UY30472A1 (es) 2008-02-29
CL2007001973A1 (es) 2008-04-04
ECSP099044A (es) 2009-02-27
US20080009482A1 (en) 2008-01-10
EP2046793A2 (en) 2009-04-15
CA2656936A1 (en) 2008-01-10
IL196207A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
JP2009542613A (ja) 新規化合物
JP7644517B2 (ja) Kras突然変異型タンパク質阻害剤
CN114555593A (zh) 作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物
EP3596073B1 (en) Tricyclic compounds for use in treatment of proliferative disorders.
US9738649B2 (en) Tetrahydro-pyrimidoazepines as modulators of TRPV1
MX2008016203A (es) Ciclopenta [d] pirimidinas como inhibidores de la proteina cinasa akt.
KR20160145796A (ko) BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
CA2753236A1 (en) Pyrrolopyrimidines used as kinase inhibitors
EP3993802A1 (en) Heterocyclic compounds as kinase inhibitors
KR20090024110A (ko) 키나제 억제제로서의 3-치환된 N-(아릴- 또는 헤테로아릴)-피라졸로[1,5-a]피리미딘
CN101448830A (zh) 作为抗增殖剂的二氢碟啶化合物
WO2010136778A1 (en) Dibenzothiophene derivatives as dna- pk inhibitors
WO2021084266A1 (en) Bicyclic nitrogen containing heterocycles as inhibitors of salt-inuced kinase sik2
CN118702697A (zh) 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
JP2025530793A (ja) Egfr阻害剤及びその使用
HK1129888B (en) 6,7,8,9-tetrahydro-5h-pyrimido[4,5-d]azepin-4-yl]-amine derivatives as modulators of trpv1 for the treatment of pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100614

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20111118